Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside
Annexon, Inc.'s average stock price target has been increased to $15.71 from $15 by 7 analysts, with forecasts ranging from $7 to $27 per share. This new target suggests a potential upside of approximately 198% based on the recent closing price. The consensus rating for ANNX remains a "Buy" from 10 analysts.
Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX
Bank of America Corp DE significantly increased its stake in Annexon, Inc. (NASDAQ:ANNX) during the first quarter, now holding 4,259,995 shares valued at $23.60 million. Other institutional investors have also adjusted their positions, and a company director recently acquired over 600,000 shares. Annexon, a clinical-stage biotechnology company focusing on neurodegenerative and neuroimmune diseases, has seen varied analyst ratings, with an average "Hold" rating and a target price of $15.33.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to three new non-executive employees under the 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These employees received options to purchase 287,500 shares of Annexon common stock at an exercise price of $5.29, vesting over four years. This initiative aims to attract and retain talent for the biopharmaceutical company focused on neuroinflammatory diseases.
At $5.29, Annexon grants new employees options vesting over four years
Annexon (Nasdaq: ANNX) announced inducement grants of options to purchase 287,500 shares of common stock to three new non-executive employees. These options, granted at an exercise price of $5.29 per share, vest over four years, with 25% on the first anniversary and the remainder monthly. The grants were made under the 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen
Wall Street Zen has downgraded Annexon (NASDAQ:ANNX) from a "sell" to a "strong sell" rating. This decision comes despite some other analysts maintaining "buy" or "hold" ratings for ANNX, with a consensus price target of $15.33. The company recently reported Q2 earnings, missing analyst estimates, and has seen significant insider stock purchases.
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed
Annexon (ANNX) experienced a 6.1% decline in share price following the adoption of a dual primary endpoint in its ARCHER II trial for vonaprument, affecting its investment narrative. Despite a wider Q2 2026 net loss of US$55.35 million, the company secured up to US$200 million in non-dilutive financing, extending its cash runway into 2028. This shift introduces a second assessment point at Month 24 for the trial, potentially broadening regulatory evaluation of the drug's vision-preserving benefits.
Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise
An individual affiliated with Annexon, Inc. (ANNX) has filed a Form 144 notice indicating an intent to sell 2,000 shares of common stock on August 13, 2026. These shares will be acquired through a same-day stock option exercise for cash. The filing also reports prior sales by Thomas Wiggans in July 2026, totaling 3,000 shares for an aggregate of $18,235.00.
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27
This article provides an overview of Annexon (ANNX.US) stock ratings from four analysts in the last quarter, with a consensus price target ranging from $8 to $27. The analysts show a generally bullish sentiment, reflected in their diverse ratings and price targets, indicating varying perspectives on the company's future performance.
Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp
Citizens JMP upgraded Annexon (NASDAQ:ANNX) from "underperform" to "market perform," while the overall analyst consensus remains a "Hold" with an average price target of $15.33. The company recently reported a quarterly loss of $0.28 per share, missing consensus estimates. Investors are looking ahead to clinical and funding catalysts, including potential 2026 data readouts and regulatory milestones, with current funding expected to last into 2028.
Annexon shares fall 6% on wider-than-expected quarterly loss
Annexon (NASDAQ:ANNX) reported a second-quarter loss of $0.28 per share, which was wider than the analyst consensus of $0.24 per share, leading to a 6.37% fall in pre-market trading. The biopharmaceutical company attributed the increased loss to higher spending on its late-stage clinical programs, including the Phase 3 ARCHER II trial for geographic atrophy. Despite the wider loss, Annexon highlighted significant clinical progress and secured a $200 million credit facility to extend its financial runway into 2028.
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon, Inc. has announced an expansion to its Phase 3 ARCHER II trial for vonaprument, a treatment for dry age-related macular degeneration with geographic atrophy. The expansion includes adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint, alongside launching an open-label extension study. This strategy aims to maximize vonaprument's potential to preserve visual acuity and allows for longer-term evaluation of the drug's profile without altering the ongoing study operations.
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in its Guillain-Barré syndrome (GBS) and geographic atrophy (GA) programs. The company expects a BLA submission for Tanruprubart in GBS in Q4 2026 and anticipates Month 15 primary endpoint data for Vonaprument in GA in the same quarter, with an expanded dual primary endpoint strategy. Annexon also secured a $200 million credit facility, extending its cash runway into 2028.
Annexon Releases Q2 2026 Financial Results
Annexon, Inc. (ANNX) reported a Q2 2026 basic and diluted loss per share of $0.28, an improvement from $0.34 in the prior year. The clinical-stage biopharmaceutical company posted a net loss of $55.3 million as it continues to invest in its pipeline for inflammatory-related diseases. Wall Street analysts hold a generally positive outlook on the company, with a consensus of 10 buy ratings.
Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.05 EPS
Annexon (NASDAQ:ANNX) reported second-quarter earnings, missing analysts' consensus estimates by $0.05 with a loss of $0.28 per share. Despite the earnings miss, the company highlighted positive clinical trial data for tanruprubart in Guillain-Barré syndrome and expanded its ARCHER II geographic atrophy trial. Annexon also secured up to $200 million in non-dilutive financing, extending its cash runway into 2028.
Annexon Q2 Earnings Call Highlights
Annexon (ANNX) announced an expansion of its ARCHER II trial for vonaprument in geographic atrophy, adding a 24-month primary endpoint to capture longer-term efficacy data, alongside the existing 15-month endpoint. The company also provided updates on its Guillain-Barré syndrome (GBS) program, with tanruprubart advancing toward regulatory filings in Europe and the U.S., and reported initial positive results from its FORWARD study. Additionally, Annexon secured a $200 million credit facility, extending its cash runway into 2028.
Earnings call transcript: Annexon misses Q2 2026 EPS view as shares fall premarket
Annexon reported a wider-than-expected Q2 2026 loss of $0.28 per share, leading to a 6.37% premarket stock decline. Despite the earnings miss, the clinical-stage biotech highlighted positive clinical progress for its Guillain-Barré syndrome program, tanruprubart, and expanded the ARCHER II geographic atrophy trial to include a 24-month endpoint to strengthen its long-term profile. The company secured a $200 million credit facility, extending its cash runway into 2028, aiming to translate clinical advancements into new medicines and shareholder value.
Annexon (Nasdaq: ANNX) deepens pipeline, adds $200M credit facility and new endpoints
Annexon (Nasdaq: ANNX) reported its second-quarter 2026 financial results, including a net loss of $55.3 million, but also announced a new $200 million credit facility to extend its cash runway into 2028. The company is advancing its neuroinflammatory pipeline, expanding the Phase 3 ARCHER II trial for vonaprument in geographic atrophy with a dual primary endpoint and anticipating key milestones like a BLA submission for tanruprubart and proof-of-concept data for ANX1502 in late 2026 and 2027. Despite ongoing losses, Annexon highlights strengthened liquidity and progress in its clinical programs for Guillain-Barré syndrome and geographic atrophy.
Tanruprubart Shows Rapid Responses in First FORWARD Cohort for Guillain-Barre Syndrome
Annexon reported rapid, clinically meaningful improvements in strength among all 10 patients in the first US and European cohort of its open-label FORWARD study for Guillain-Barré syndrome (GBS) following a single tanruprubart infusion. These results, including ambulation for bedbound patients and ventilator liberation, are consistent with prior phase 3 and real-world evidence. Tanruprubart, which targets C1q to inhibit neuroinflammation, is currently under EMA review, and FORWARD data will support a planned FDA BLA submission in Q4 2026.
Form 8K Annexon Inc For: 10 August By Investing.com
This article announces the filing of Form 8K by Annexon Inc. on August 10. The content itself is very brief, serving primarily as a notification of the regulatory filing and is published by Investing.com. It also includes various market data, news headlines, and stock performance figures from Investing.com.
Annexon names Mark Blumenkranz to board as Muneer Satter steps down
Annexon has appointed retinal surgeon and biotech entrepreneur Mark S. Blumenkranz to its board of directors. Blumenkranz, a Stanford ophthalmology professor emeritus and co-director of its Ophthalmic Innovation Program, has extensive experience in the ophthalmic industry, having co-founded Adverum Biotechnologies and led several companies through acquisitions. Concurrently, director Muneer Satter has stepped down from the board.
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon, Inc. has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings extensive experience in advancing therapies for retinal diseases, aligning with Annexon's focus on neuroinflammatory diseases. Concurrently, Muneer Satter will step down from the board after 11 years of service.
Form 8K Annexon Inc For: 10 August By Investing.com
This article announces that Annexon Inc. filed a Form 8K on August 10th. The filing is brief and does not contain additional details beyond the date of the filing and the company involved.
Annexon appoints retinal surgeon Blumenkranz to board By Investing.com
Annexon, Inc. (NASDAQ:ANNX) has appointed retinal surgeon Mark S. Blumenkranz, M.D., M.M.S., to its board of directors. Concurrently, Muneer Satter will step down from the board after more than 11 years of service. Blumenkranz brings extensive experience from Stanford University and has co-founded several ophthalmic and life sciences companies.
Annexon names Mark Blumenkranz to board as Muneer Satter steps down
Annexon has appointed retinal surgeon and biotech entrepreneur Mark S. Blumenkranz to its board of directors. Blumenkranz, a Stanford ophthalmology professor emeritus and co-director of its Ophthalmic Innovation Program, has a strong background in founding and leading ophthalmic companies. This appointment follows the stepping down of director Muneer Satter from the board.
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon, Inc. (Nasdaq: ANNX) has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings over four decades of experience in retinal disease innovation, which will be crucial as Annexon advances its late-stage clinical programs. Concurrently, Muneer Satter has stepped down from the board after more than 11 years of service.
Renaissance Technologies LLC Sells 258,300 Shares of Annexon, Inc. $ANNX
Renaissance Technologies LLC reduced its stake in Annexon, Inc. (NASDAQ:ANNX) by 32.2%, selling 258,300 shares but still retaining 544,300 shares valued at approximately $3.0 million. While Renaissance Technologies reduced its holdings, other institutional investors like AQR Capital Management and Acadian Asset Management increased their positions. Notably, Annexon insiders, including Director William Carson and Director Muneer Satter, also made significant purchases, with insiders collectively owning 10.31% of the company.
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Annexon, Inc. announced early positive results from the first ten U.S. and European patients in its open-label FORWARD study for Guillain-Barré syndrome (GBS) treated with tanruprubart. The study demonstrated rapid, clinically meaningful improvements in strength and reduced disability within days of a single infusion, consistent with previous Phase 3 and Real-World Evidence findings. This drug has the potential to be the first approved targeted therapy for GBS worldwide, addressing a significant unmet need and high healthcare burden.
Annexon Inc (ANNX) Stock News Today
This article provides an update on Annexon Inc (ANNX) stock news, earnings, analyst ratings, and key developments. It notes that more news is expected soon and invites users to stay tuned. The article also presents current stock performance data for ANNX.
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27
Wells Fargo has reaffirmed its Buy rating on Annexon (ANNX.US), holding its target price at $27. This continued endorsement suggests the firm's confidence in Annexon's future performance.
State Street Corporation (ANNX) discloses 9.8M-share, 6% holding in Annexon
State Street Corporation has disclosed a 6% holding in Annexon Inc. (ANNX), amounting to 9,824,321 common shares, as per a Schedule 13G filing. The shares are held for passive investment purposes with shared voting power over 9,572,419 shares and shared dispositive power over all 9,824,321 shares. This stake is managed through various State Street Global Advisors investment management subsidiaries.
Goldman Sachs reiterates Neutral on Annexon stock after GBS data
Goldman Sachs has reiterated a Neutral rating and $7.00 price target on Annexon Biosciences (NASDAQ: ANNX) following the release of initial data from its FORWARD study for Guillain-Barré syndrome (GBS). The study showed rapid and meaningful improvement in patients, supporting a planned biologics license application. The firm estimates peak sales of approximately $850 million for the treatment, tanruprubart, while awaiting more detailed data and the Phase 3 ARCHER II data for vonaprument.
Annexon, Inc. Reports Early Clinical Responses in First U.S. and European Patient Cohort of GBS FORWARD Study with Tanruprubart
Annexon, Inc. announced early positive results from the first ten U.S. and European patients in its GBS FORWARD study of tanruprubart. The study showed rapid and clinically meaningful improvements in strength and reduced disability within days for patients with Guillain-Barré syndrome (GBS), a life-threatening neuroinflammatory disease. These outcomes are consistent with Phase 3 results and will support Annexon's planned Biologics License Application (BLA) submission in Q4 2026.
Form 8K Annexon Inc For: 6 August By Investing.com
This article announces the filing of a Form 8K by Annexon Inc. on August 6. It provides no further details about the content of the 8K, simply stating its publication date and the company involved. The article is very brief and includes only the headline and the company's stock symbol with a minor price change.
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $25
Needham has reiterated its Buy rating on Annexon (ANNX.US) and maintained its price target of $25. This indicates continued confidence in the company's prospects.
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Annexon, Inc. announced rapid and clinically meaningful improvements in strength and reduced disability with tanruprubart in the first ten U.S. and European patients in its GBS FORWARD study. All treated patients showed rapid improvement within four days, with some bedbound patients walking within days and one ventilated patient coming off the ventilator quickly. These early results are consistent with prior Phase 3 and real-world evidence studies, reinforcing tanruprubart's potential as a targeted therapy for Guillain-Barré syndrome and supporting future regulatory submissions.
Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients
Annexon reported positive early results from its FORWARD study for Guillain-Barré syndrome, demonstrating rapid functional and strength gains in all ten treated patients within approximately one week. The company noted that patients, including severe cases, showed quicker recovery than expected, and the safety profile was consistent with previous findings. Annexon plans to present additional data at upcoming medical conferences and aims for a Biologics License Application (BLA) submission in Q4 2026, while tanruprubart is also under review by the European Medicines Agency.
Annexon Announces Positive Clinical Outcomes from GBS FORWARD Study on Tanruprubart
Annexon, Inc. reported positive clinical outcomes from the initial U.S. and European patient cohort of its GBS FORWARD Study. The study is evaluating tanruprubart, and the findings were disclosed in a current report filed with the SEC on August 6, 2026. This announcement highlights significant progress in the development of tanruprubart.
Form 8K Annexon Inc For: 6 August By Investing.com
This article from Investing.com reports on an 8K filing by Annexon Inc. for August 6th, 2026. The content provides basic details of the filing along with an image credited to Reuters. The article itself is very brief and mostly surrounded by financial market data, news headlines, and promotional content from Investing.com.
Annexon (ANNX) Projected to Post Earnings on Thursday
Annexon (NASDAQ:ANNX) is projected to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts expecting a loss of $0.23 per share and revenue of $6.50 million. The company's stock recently traded near $5.37, and analyst sentiment is mixed, resulting in a consensus Hold rating and a $15.33 price target. Recent insider buying activity includes significant purchases by director Muneer A. Satter and William H. Carson.
Annexon secures USD 200m credit facility to fund late-stage programs through potential commercial launch
Annexon, Inc. has secured a senior secured credit facility of up to $200 million from Oxford Finance LLC. This non-dilutive capital is intended to fund the company's late-stage programs, tanruprubart and vonaprument, through potential commercial launch, avoiding additional equity dilution. The funding is tied to milestones in their registrational programs, with an initial $50 million already drawn and further tranches dependent on regulatory and clinical progress.
Annexon, Inc. (NASDAQ:ANNX) Receives Average Recommendation of "Hold" from Analysts
Annexon, Inc. (NASDAQ:ANNX) has received an average "Hold" recommendation from ten analysts, with a 12-month average price target of $15.33 against its recent trading price of $5.07. Insider transactions show significant share purchases by directors William H. Carson and Muneer A. Satter, increasing insider ownership to 10.31%. The clinical-stage biotech reported a smaller-than-expected quarterly loss and is developing complement-targeted therapies like ANX005 for neurodegenerative and neuroimmune diseases.
BlackRock, Inc. Expands Stake in Annexon Inc (ANNX) with Strategic Share Acquisition
BlackRock, Inc. has significantly increased its stake in Annexon Inc (ANNX) by acquiring over 2.1 million shares, bringing its total holdings to 13.1 million shares, representing an 8% position. This strategic move highlights BlackRock's calculated bet on the long-term potential of the clinical-stage biopharmaceutical company, despite Annexon's current unprofitability and high-risk profile. The acquisition suggests confidence in Annexon's pipeline of therapies targeting classical complement-mediated disorders, even as the stock experiences volatility.
Annexon secures $200M credit facility with Oxford Finance
Annexon, Inc. (NASDAQ:ANNX) has secured a credit facility worth up to $200 million with Oxford Finance LLC to fund its drug development programs for neuroinflammatory diseases. The biopharmaceutical company received an initial $50 million, with additional funds tied to the achievement of milestones for its vonaprument and tanruprubart registrational programs. This non-dilutive capital is expected to bolster Annexon's financial and operational capabilities as it moves towards potential global commercialization.
Annexon Secures Up to $200 Million Term Loan Facility With Oxford Finance
Annexon (ANNX) has secured a term loan facility of up to $200 million from Oxford Finance for working capital and general corporate purposes. An initial $50 million was funded at signing, with additional tranches totaling up to $150 million tied to milestones and mutual agreement. The loans feature a floating interest rate and interest-only payments through September 2029, with a maturity date between July 2031 and June 2032.
Annexon (Nasdaq: ANNX) obtains up to $200M credit facility from Oxford
Annexon, Inc. secured a credit facility of up to $200 million from Oxford Finance LLC to support its working capital and general business requirements, including advancing its vonaprument and tanruprubart registrational programs. An initial $50 million was funded at closing, with additional tranches tied to milestone achievements. The loans bear interest at a floating rate with a floor of 7.60% and mature between July 2031 and June 2032, with an initial interest-only payment period.
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Annexon, Inc. has entered into a strategic credit facility agreement with Oxford Finance LLC for up to $200 million. This non-dilutive capital aims to enhance Annexon's financial and operational capabilities as its vonaprument and tanruprubart programs advance toward registration and potential global commercialization. An initial $50 million was drawn at closing, with additional funds contingent on achieving specific milestones related to these programs.
Annexon secures credit facility of up to $200 million from Oxford Finance
Annexon has secured a strategic credit facility of up to $200 million from Oxford Finance. An initial $50 million was drawn at closing, with an additional $100 million contingent on milestones for vonaprument and tanruprubart registrational programs. The remaining $50 million is subject to lender approval.
Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Annexon Inc (ANNX), detailing its performance based on various indicators and moving averages. It presents a summary of technical indicators like MACD, RSI, and CCI, as well as moving average values from MA5 to MA200, highlighting neutral and sell signals. The analysis aims to offer investment reference without providing financial advice, and includes an FAQ section explaining technical ratings and moving averages.
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Annexon, Inc. (Nasdaq: ANNX) has secured a strategic credit facility of up to $200 million from Oxford Finance LLC to bolster its financial capacity as its vonaprument and tanruprubart programs advance toward registration. The initial draw is $50 million, with additional funds contingent on achieving specific milestones for its key clinical programs. This non-dilutive capital aims to strengthen Annexon's balance sheet and accelerate its growth strategy for developing targeted immunotherapies for neuroinflammatory diseases.
Several Annexon Insiders Sell Shares Sending Potential Negative Signal
The article reports that several Annexon insiders have sold shares, potentially signaling a negative outlook for the company. This move often raises concerns among investors regarding the company's future performance.
